Gael Forterre - 01 Jun 2025 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Signature
/s/ Gael Forterre
Issuer symbol
VNRX
Transactions as of
01 Jun 2025
Net transactions value
-$2,130
Form type
4
Filing time
03 Jun 2025, 16:06:00 UTC
Previous filing
05 May 2025
Next filing
03 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Forterre Gael Chief Commercial Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON /s/ Gael Forterre 03 Jun 2025 0001841637

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNRX Common Stock Award $0 +6,690 +4.2% $0.000000 165,696 01 Jun 2025 Direct F1
transaction VNRX Common Stock Tax liability $2,130 -4,234 -2.6% $0.5030 161,462 01 Jun 2025 Direct F2
holding VNRX Common Stock 5,000 01 Jun 2025 By Spouse
holding VNRX Common Stock 32,500 01 Jun 2025 By Armorica Partners, LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 1, 2025, the reporting person was awarded 6,690 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 2,230 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
F2 Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,240 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.
F3 These shares of common stock are managed by Armorica Partners, LLC (formerly Armori Capital Management, LLC) ("Armorica Partners"). Mr. Forterre is the managing director and sole shareholder of Armorica Partners and has voting and dispositive control over the shares held by Armorica Partners. Mr. Forterre disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.